Methotrexate vs Azathioprine for Myasthenia Gravis
Author Information
Author(s): Heckmann Jeannine M, Rawoot Amanullah, Bateman Kathleen, Renison Rudi, Badri Motasim
Primary Institution: University of Cape Town
Hypothesis
Is methotrexate an effective steroid-sparing agent compared to azathioprine in generalized myasthenia gravis?
Conclusion
Methotrexate is an effective steroid-sparing agent in generalized myasthenia gravis, showing similar efficacy and tolerability to azathioprine.
Supporting Evidence
- Patients receiving methotrexate had lower prednisone doses at months 10 and 12.
- Both treatment groups achieved similar proportions of sustained minimal manifestation status.
- Adverse events were similar between both groups, with some differences in types.
Takeaway
This study found that methotrexate can help people with a condition called myasthenia gravis use less of a strong medicine called prednisone, just like another medicine called azathioprine.
Methodology
A randomized, single-blind study comparing methotrexate and azathioprine in patients with generalized myasthenia gravis over 24 months.
Potential Biases
Socioeconomic factors prevented some subjects from being randomized, which may introduce bias.
Limitations
The study had a small sample size and was halted due to slow recruitment.
Participant Demographics
Participants included both AChR-Ab-positive and AChR-Ab-negative myasthenia gravis patients.
Statistical Information
P-Value
p = 0.019
Confidence Interval
95% CI 0.12; 20.21
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website